Vaccine Effectiveness of 3 Versus 2 Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in a High-Risk National Population.

Adeel Ajwad ButtVictor B TalisaPeng YanObaid S ShaikhSaad B OmerFlorian B Mayr

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)

A third dose of a SARS-CoV-2 mRNA vaccine is associated with high VE against symptomatic infection, hospitalization, and critical disease in the pre-Omicron era.

Keyphrases

sars cov
respiratory syndrome coronavirus
coronavirus disease
randomized controlled trial
systematic review
binding protein